

ASX Release

**U.S.-Based Duke Clinical Research Institute and
TALi to Study Game-Based Assessment Tools for
Cognitive Impairment in Children****Highlights**

- Research collaboration to expand on TALi's research initiatives to generate international clinical evidence for its ground breaking, game-based technology platform that measures and develops attention skills in early childhood
- The Duke Clinical Research Institute (DCRI), part of the Duke University School of Medicine, is the world's largest academic clinical research organisation
- Scott Kollins, PhD, Professor in Psychiatry and Behavioral Sciences at Duke and Co-Director of the DCRI's Digital Health Solutions group, to serve as research primary investigator

TALi Digital Ltd (ASX:TD1), a leading health technology business, will work with the Duke Clinical Research Institute (DCRI) located in Durham, North Carolina, in the United States of America (USA), to conduct clinical research programs to evaluate TALi's cognitive assessment tool developed to evaluate attention-related abilities for children aged between three and eight years.

TALi Digital Managing Director, Mr Glenn Smith, said: "Our goal is to be a global leader in the assessment and treatment of childhood attention difficulties, specifically during early childhood, a period of peak neuroplasticity and cognitive development.

"Our collaboration with the DCRI reflects our commitment to assisting children in reaching their full potential by undertaking clinical research that will evaluate our technology platform's ability to improve core cognitive performance. We are excited to work with the DCRI, which has a proven track record of designing innovative large-scale, longitudinal studies for cognitive disorders in paediatric populations," said Mr Smith.

Professor in Psychiatry and Behavioral Sciences at Duke and Co-Director of the DCRI's Digital Health Solutions group, Professor Scott Kollins, PhD, said: "We welcome the opportunity to develop clinical research studies that will expand the clinical evidence base for novel and innovative digital tools to identify and treat the symptoms of inattention at a young age.

"The DCRI has extensive experience working with developers of digital therapeutics to provide clinical research and an evidence framework needed for TALi to comply with the requirements of regulators, government agencies, and commercial partners," added Mr Smith. "Collaborations like the one with the DCRI demonstrate the potential for TALi to have a tremendous impact on the lives of children and their broader communities," said Professor Kollins.

The first project that will be conducted as part of this collaboration will begin this year and forms part of TALi's research and international development strategy.

Release authorised by:

Glenn Smith
TALi Digital Managing Director

ABOUT TALi DIGITAL

TALi Digital Limited (ASX:TD1) a leading health technology business is seeking to improve attention in early childhood through its breakthrough TALi platform. TALi combines evidence-based proprietary algorithms inside a game-based program to assess and strengthen core attention skills. Learn more at talihealth.com.

CONTACT

General + Investor Enquiries

Glenn Smith
TALi Digital Managing Director
p. 1300 082 013
e. info@talihealth.com

Media enquiries

Haley Chartres
HACK Director
p. +61 423 139 163
e. haley@hck.digital